Table 3. Estimates of hazard ratios and incidence rates (per 1000 person-year for the primary and secondary endpoints according to the statin responses in the subgroup of on-treatment low-density lipoprotein cholesterol ≤55 mg/dL).
| Group: LDL ≤55 mg/dL (n=287) | CVD events (n) | Rate of CVD events (per 1000 person-years) | HR (adjusted)a (95%CI) | p-value | |
|---|---|---|---|---|---|
| MACE | Optimal | 15 | 16.9 | 1 | <0.001 |
| Suboptimal | 19 | 61.2 | 8.73 (2.81–27.1) | ||
| Cardiovascular death | Optimal | 1 | 1.1 | 1 | – |
| Suboptimal | 3 | 9.6 | 1 | ||
| Reinfarction | Optimal | 2 | 2.2 | 1 | 0.01 |
| Suboptimal | 6 | 19.2 | 14,7 (1.72–126.3) | ||
| Recurrent myocardial infarction | Optimal | 10 | 11.2 | 1 | 0.002 |
| Suboptimal | 14 | 45.1 | 5.89 (1.89–18.3) | ||
| Target vessel revascularization, n (%) | Optimal | 15 | 16.9 | 1 | 0.001 |
| Suboptimal | 16 | 51.5 | 7.93 (2.49–25.2) |
LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; MACE: major adverse cardiovascular events.
a
The multivariable Cox regression models for MACE, cardiovascular death, reinfarction, recurrent myocardial infarction, and target vessel revascularization were adjusted for prior myocardial infarction, prior coronary revascularization, baseline LDL-C, baseline total cholesterol, baseline triglyceride, baseline HDL-C, on-treatment LDL-C, and hs-CRP levels. Bold values indicate statistical significance at the p<0.05 level.